A prospective analysis of risk factors for the discontinuation of second-line antirheumatic drugs
- 1 September 1993
- journal article
- Published by Springer Nature in International Journal of Clinical Pharmacy
- Vol. 15 (5) , 203-207
- https://doi.org/10.1007/bf01880627
Abstract
No abstract availableKeywords
This publication has 29 references indexed in Scilit:
- Validity of single variables and composite indices for measuring disease activity in rheumatoid arthritis.Annals of the Rheumatic Diseases, 1992
- Comparison between Sodium Aurothiomalate and Auranofin in Rheumatoid Arthritis:Results of a Two-year Open Randomized StudyScandinavian Journal of Rheumatology, 1987
- Comparison of White Blood Cell Dyscrasias during Sulphasalazine1 Therapy of Rheumatoid Arthritis and Inflammatory Bowel DiseaseDrugs, 1986
- FENCLOFENAC-INDUCED SELECTIVE IGA DEFICIENCY IN RHEUMATOID ARTHRITISRheumatology, 1985
- PRACTICAL RESULTS OF TREATMENT WITH DISEASE-MODIFYING ANTIRHEUMATOID DRUGSRheumatology, 1985
- Serum IgA and gold-induced toxic effects in patients with rheumatoid arthritisArchives of internal medicine (1960), 1984
- Outcome of attempts to treat rheumatoid arthritis with gold, penicillamine, sulphasalazine, or dapsone.Annals of the Rheumatic Diseases, 1984
- Serum IgA concentration and hepatotoxicity in rheumatoid arthritis treated with azathioprine.BMJ, 1983
- Some Characteristics of RA Patients with and Without Side Effects Due to Gold TreatmentScandinavian Journal of Rheumatology, 1977
- Proceedings: Factors governing safety and success of gold salt therapy in rheumatoid arthritis (RA). A prospective study.Annals of the Rheumatic Diseases, 1975